Exact Sciences raises $25m as it advances colorectal cancer screening
This article was originally published in Clinica
Executive Summary
Exact Sciences, a US molecular diagnostics company, has announced the pricing of a public offering of 3.125 million shares of its common stock at $8 per share. The net proceeds, projected at $23.6m, are expected to be used to gain FDA approval of its stool-based DNA colorectal cancer screening test, and other uses.